Autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia is safe but poses challenges for long-term maintenance of molecular remission: Results of the Auto-Ph17 study.
Article in EJHaem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors at 9 institutions in 1 country.
Satoshi NishiwakiDepartment of Advanced Medicine Nagoya University Hospital Nagoya Japan.
Isamu SugiuraDivision of Hematology and Oncology Toyohashi Municipal Hospital Toyohashi Japan.
Takahiko SatoDepartment of Immunology Nagoya University Graduate School of Medicine Nagoya Japan.
Miki KobayashiDepartment of Hematology and Oncology Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital Nagoya Japan.
Masahide OsakiDepartment of Hematology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Masashi SawaDepartment of Hematology and Oncology Anjo Kosei Hospital Anjo Japan.
Yoshitaka AdachiDepartment of Hematology and Oncology JA Aichi Konan Kosei Hospital Konan Japan.
Motohito OkabeDepartment of Hematology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Shigeki SaitoDepartment of Hematology and Oncology Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital Nagoya Japan.
Takanobu MorishitaDepartment of Hematology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan.
Akio KohnoDepartment of Hematology and Oncology JA Aichi Konan Kosei Hospital Konan Japan.
Takahiro NishiyamaDivision of Hematology Ichinomiya Municipal Hospital Ichinomiya Japan.
Hiroatsu IidaDepartment of Hematology National Hospital Organization Nagoya Medical Center Nagoya Japan.
Shingo KurahashiDivision of Hematology and Oncology Toyohashi Municipal Hospital Toyohashi Japan.
Yachiyo KuwatsukaDepartment of Advanced Medicine Nagoya University Hospital Nagoya Japan.
Daisuke SugiyamaDepartment of Immunology Nagoya University Graduate School of Medicine Nagoya Japan.
Sachiko ItoDepartment of Immunology Nagoya University Graduate School of Medicine Nagoya Japan.
Hiroyoshi NishikawaDepartment of Immunology Nagoya University Graduate School of Medicine Nagoya Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology Nagoya University Graduate School of Medicine Nagoya Japan.
Nagoya University · JPJapanese Red Cross Nagoya Daiichi Hospital · JPJapanese Red Cross Nagoya Daini Hospital · JPKonan Kosei Hospital · JPNagoya University Hospital · JPToyohashi Municipal Hospital · JPAnjo Kosei Hospital · JPIchinomiya Municipal City Hospital · JPNagoya Medical Center · JP
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Autologous hematopoietic stem cell transplantation (SCT) is not a standard treatment option for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL); however, its position has been reassessed since the introduction of tyrosine kinase inhibitors (TKIs). We prospectively analyzed the efficacy and safety of autologous peripheral blood SCT (auto-PBSCT) for Ph+ALL patients aged between 55 and 70 years who had achieved complete molecular remission. Melphalan, cyclophosphamide, etoposide, and dexamethasone were used for conditioning. A total of 12 courses of maintenance therapy, including dasatinib, were performed. The required number of CD34
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia is safe but poses challenges for long-term maintenance of molecular remission: Results of the Auto-Ph17 study. · full record | OpenQuestion